It’s been rough times for the development of Alzheimer’s drugs. Last month, Myriad Genetics said its late-stage trial of its experimental drug Flurizan failed to show any benefit for Alzheimer’s patients. Another late-stage study, of Alzhemed from Canada’s Neurochem, failed last fall.
The results of the Flurizan study will be unpacked this week at a big [...]
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment